MAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, 'BioNTech' or 'the Company') held its Annual General Meeting ('AGM') today. A total of 92 per cent of the share capital was represented
MAINZ, Germany, May 15, 2026 -- BioNTech SE held its Annual General Meeting today. A total of 92 per cent of the share capital was represented at the virtual assembly.
All resolutions proposed on the agenda items put to the vote at today's AGM were approved by a majority of the shareholders. BioNTech is strengthening its focus on the Company's growing late-stage oncology pipeline, while continuing its discovery and early research aimed at long-term innovation.
Consequently, the Company's shareholders approved expanding the Supervisory Board from six to eight members and adding additional expertise: Prof. Iris Löw-Friedrich, M.D., Ph. D., and Susanne Schaffert, Ph. D., were elected as new members of the Supervisory Board. Iris Löw-Friedrich has many years of expertise in the field of clinical development and broad experience in the scientific and medical fields.
She also possesses knowledge in the areas of sales and commercialization, management, innovation, and international markets relevant to the Company. She is an experienced Supervisory Board member and adjunct professor of internal medicine at the faculty of medicine at Goethe University in Frankfurt am Main, Germany. Susanne Schaffert is a member of supervisory boards in the healthcare sector, including that of Merck KGaA.
She possesses particular expertise in the field of oncology as well as in sales and commercialization with a focus on product launches. Her knowledge spans innovation, research and development, and organizational leadership and management.
Additionally, shareholders approved the extension of the mandates of BioNTech's Supervisory Board members Helmut Jeggle, Prof. Anja Morawietz, Ph. D., and Prof. Rudolf Staudigl, Ph. D.At a meeting held following the AGM, the Supervisory Board elected Helmut Jeggle as its Chairman. The voting results for all agenda items can be viewed on the Annual General Meeting 2026 website under the section 'Voting Results'.
The speeches by Chief Executive Officer Prof. Ugur Sahin, M.D., Chief Financial Officer Ramón Zapata and the slides presented at the AGM 2026 can be found in section 'Speeches and Presentations' under the same link. About BioNTech BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated.
Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies.
BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer. For more information, please visit www. BioNTech.com.
BioNTech Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning the potential benefits of appointed Supervisory Board members. In some cases, forward-looking statements can be identified by terminology such as"will,""may,""should,""expects,""intends,""plans,""aims,""anticipates,""believes,""estimates,""predicts,""potential,""continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.
The forward-looking statements in this press release are based on BioNTech's current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements.
You should review the risks and uncertainties described under the heading"Risk Factors" in BioNTech's Report on Form 6-K for the period ended March 31, 2026, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at www.sec.gov. These forward-looking statements speak only as of the date hereof.
Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. CONTACTS Investor Relations Douglas Maffei, PhD Investors@biontech.de Media Relations Jasmina Alatovic Media@biontech.de © 2026 GlobeNewswire Vergessen Sie Gold, Silber und Öl: Nächste Megarallye startet! Die Märkte feiern neue Rekorde – doch im Hintergrund braut sich eine Entwicklung zusammen, die alles verändern könnte.
Die anhaltende Sperrung der Straße von Hormus sorgt laut IEA für eine der größten Energiekrisen aller Zeiten. Gleichzeitig schießen die Preise für Düngemittel und Agrarrohstoffe bereits nach oben. Damit droht ein perfekter Sturm: steigende Energiepreise, explodierende Produktionskosten und ein möglicher Super-El-Nino, der weltweit Ernten gefährdet. Erste Auswirkungen sind längst sichtbar – Weizen, Soja und Kakao verteuern sich deutlich, während Lebensmittelpreise vor dem nächsten Sprung stehen könnten.
Für Anleger bedeutet das nicht nur Risiken, sondern enorme Chancen. Denn während klassische Märkte unter Druck geraten könnten, entsteht auf den Feldern und Plantagen der nächste große Rohstoffzyklus. Wer sich jetzt richtig positioniert, kann von einer Entwicklung profitieren, die weit über Öl und Metalle hinausgeht. In unserem aktuellen Spezialreport stellen wir drei Aktien vor, die besonders aussichtsreich sind, um von diesem Trend zu profitieren – solide positioniert, strategisch relevant und mit erheblichem Aufwärtspotenzial.
Jetzt den kostenlosen Report sichern – bevor der Agrar-Boom voll durchschlägt! Hier klicken
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Virtual Hauptversammlung of Heidelberg Pharma AGThe board of Heidelberg Pharma AG has decided to hold the annual general meeting as a virtual event, excluding the presence of the company's designated representatives. The virtual event will be broadcast live on the company's website and accessible through the virtual meeting platform. The virtual platform will allow shareholders to participate in the meeting, exercise their voting rights, delegate their voting powers, submit questions, proposals, and statements, and exercise their right to information and appeal decisions. The virtual platform will also provide live streaming of the entire meeting in high-definition video and audio.
Read more »
BioNTech Aktie an der NASDAQ im Minus: Unternehmen setzt wieder stärker auf KerngeschäftBioNTech-Mitbegründer Ugur Sahin hat den von Jobabbau betroffenen Beschäftigten des Impfstoffherstellers Unterstützung zugesagt.
Read more »
Nach Curevac-Aus: Biontech kehrt zu seinen Wurzeln zurückDer Fokus von Biontech liegt nach dem Ende der Corona-Pandemie wieder auf der Forschung und Entwicklung von Medikamenten gegen Krebs. Das hat Folgen für Unternehmensstandorte wie Tübingen.
Read more »
CCL Industries Inc.: CCL Industries Announces 2026 Annual and Special Shareholders' Meeting ResultsTORONTO, ON / ACCESS Newswire / May 15, 2026 / CCL Industries Inc. (the 'Company' or 'CCL') (TSX:CCL.A, CCL.B), a world leader in specialty label, security and packaging solutions for global corporations
Read more »